kabutan

SAPPORO CLINICAL LAB, First Half Ordinary Profit Increases by 13%, Jul-Sep Ordinary Profit Increases by 23%

Fri Nov 7, 2025 3:30 pm JST Earnings

9776 SAPPORO CLINICAL LABORATORY INC. 【J-GAAP】

Earnings Report

SAPPORO CLINICAL LABORATORY INC. <9776> [TSE Std] announced its financial results after the market closed on November 7th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) increased 13.4% from the same period last year, reaching 389 million yen. Progress toward the full-year plan of 771 million yen was 50.5%, almost the same as the five-year average of 47.9%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to grow 4.9% from the same period last year, reaching 382 million yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit grew 22.8% from the same period last year, reaching 296 million yen. The operating profit margin improved from 4.8% in the same period last year to 5.6%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 9,862 291 296 226 67.9 57.6 Nov 10, 2023 J-GAAP
Apr - Sep, 2024 9,996 337 343 222 70.9 48.5 Nov 8, 2024 J-GAAP
Apr - Sep, 2025 10,238 379 389 250 80.4 50.5 Nov 7, 2025 J-GAAP
YoY +2.4% +12.5% +13.4% +12.6% +13.4%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance 10,312 366 365 238 76.3 0 May 12, 2025 J-GAAP
Apr - Sep, 2025 Results 10,238 379 389 250 80.4 0 Nov 7, 2025 J-GAAP
Revision Rate -0.7% +3.6% +6.6% +5.0% +5.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 10,135 369 364 242 77.4 23 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 10,450 396 382 255 81.7 23 Nov 7, 2025 J-GAAP
YoY +3.1% +7.3% +4.9% +5.4% +5.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 19,682 534 514 380 114.1 23 May 13, 2024 J-GAAP
Mar, 2025 20,131 706 707 464 148.4 23 May 12, 2025 J-GAAP
Mar, 2026 Guidance 20,688 775 771 505 161.9 23 May 12, 2025 J-GAAP
YoY +2.8% +9.8% +9.1% +8.8% +9.1%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 4,997 239 241 166 53.0 4.8 Nov 8, 2024 J-GAAP
Oct - Dec, 2024 5,279 204 210 145 46.3 3.9 Feb 12, 2025 J-GAAP
Jan - Mar, 2025 4,856 165 154 97 31.0 3.4 May 12, 2025 J-GAAP
Apr - Jun, 2025 5,066 87 93 47 15.3 1.7 Aug 4, 2025 J-GAAP
Jul - Sep, 2025 5,172 292 296 203 65.3 5.6 Nov 7, 2025 J-GAAP
YoY +3.5% +22.2% +22.8% +22.3% +23.2%

Related Articles